Avedro is seeking to gain FDA approval for its KXL Lasik device platform. The device platform has received CE Mark for sale outside of the US and is currently undergoing Phase III clinical studies within the US.
More Articles on Ophthalmology:
Miller School of Medicine, International Team Discover Seven Genes Linked to Macular Degeneration
Report Estimates Optical Imaging Market Worth $1.9B by 2018
$11.5M in Series A Funding Awarded to Kala Pharmaceuticals
$43M of Series D Funding Goes to Avedro
Avedro, a medical device and pharmaceutical company based in Waltham, Mass., has received $43 million in Series D funding from investment group Abingworth and investment adviser Third Point.
